Chief Executive Officer and Managing Director, Percheron Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Chief Executive Officer and Managing Director | Percheron Therapeutics | Biotech Dispatch, Wholesale Investor |
Stories naming Dr James Garner. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
Profile of Percheron Therapeutics, an ASX-listed biotech led by Dr James Garner, developing HMBD-002 against the VISTA protein to treat cancers that resist PD-1 immunotherapy, with Phase 2 trials planned for 2026.